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In a recent vaccine trial performed with African children, immunization with a recombinant protein based on Plasmodium fal-
ciparum apical membrane antigen 1 (AMA-1) conferred a significant degree of strain-specific resistance against malaria. To con-
tribute to the efforts of generating a vaccine against Plasmodium vivaxmalaria, we expressed the ectodomain of P. vivax AMA-1
(PvAMA-1) as a secreted soluble protein in the methylotrophic yeast Pichia pastoris. Recognized by a high percentage of sera
from individuals infected by P. vivax, this recombinant protein was found to have maintained its antigenicity. The immunoge-
nicity of this protein was evaluated in mice using immunization protocols that included homologous and heterologous prime-
boost strategies with plasmid DNA and recombinant protein. We used the following formulations containing different adju-
vants: aluminum salts (Alum), Bordetella pertussismonophosphoryl lipid A (MPLA), flagellin FliC from Salmonella enterica
serovar Typhimurium, saponin Quil A, or incomplete Freund’s adjuvant (IFA). The formulations containing the adjuvants Quil
A or IFA elicited the highest IgG antibody titers. Significant antibody titers were also obtained using a formulation developed for
human use containingMPLA or Alum plus MPLA. Recombinant PvAMA-1 produced under “conditions of good laboratory
practice” provided a good yield, high purity, low endotoxin levels, and nomicrobial contaminants and reproduced the experi-
mental immunizations. Most relevant for vaccine development was the fact that immunization with PvAMA-1 elicited invasion-
inhibitory antibodies against different Asian isolates of P. vivax. Our results show that AMA-1 expressed in P. pastoris is a
promising antigen for use in future preclinical and clinical studies.
The pursuit of a Plasmodium vivax vaccine remains a great chal-lenge. Furthermore, despite the widespread distribution of the
disease worldwide and increasing reports of morbidity and mor-
tality, research on P. vivax malaria has been neglected for many
years (1, 2). In spite of its importance and in contrast to Plasmo-
dium falciparum malaria, only three clinical trials based on sub-
unit P. vivax vaccines have been completed to date (http://www
.clinicaltrials.gov/).
One of the leading candidates for the development of a vaccine
against malaria is the transmembrane protein apical membrane
antigen-1 (AMA-1), which is characteristic of Plasmodium sp. and
formed by a cysteine-rich ectodomain, transmembrane region,
and C-terminal region (3). AMA-1 is initially expressed in sporo-
zoites (4); at the end of asexual reproduction inside hepatocytes or
erythrocytes, the expression of AMA-1 increases and the protein is
translocated to the micronemes in the apical pole (5). Recent stud-
ies have shown that the hydrophobic regions located in domain II
of P. falciparum AMA-1 bind to rhoptry neck protein 2 (RON2)
(6) to form a complex, a process that is inhibited by antibodies (7)
and peptides (8), thereby preventing invasion. These data suggest
that the AMA-1–RON complex is essential for parasite invasion.
Although experiments with conditional gene deletion have con-
firmed that AMA-1 is required for merozoite invasion of red
blood cells, it has been found to be dispensable for sporozoite
invasion of hepatocytes (9).
Many significant variations (alleles) have been observed in P.
falciparum and P. vivax isolates (10–17). The majority of P. vivax
AMA-1 (PvAMA-1) polymorphisms are described in domain I
(13–15), whereas domain II is more conserved, suggesting an im-
portant function (16, 17).
A number of phase II clinical trials using recombinant proteins
or viruses based on P. falciparum AMA-1 (PfAMA-1) have been
performed to date (18–21). Recently, a vaccine trial was con-
ducted with 400 African children using the malaria vaccine
FMP2.1/AS02A. This vaccine is a recombinant prokaryotic pro-
tein based on PfAMA-1 from the 3D7 strain ofP. falciparum and is
administered as a formulation containing the adjuvant system
AS02A (oil-in-water emulsion with 3-deacylated-monophospho-
ryl lipid A from Salmonella enterica serovar Minnesota and a
highly purified saponin, QS-21). However, the results of the pri-
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mary analyses revealed an efficacy against malaria of only 17.4%.
Due to the possibility of strain-specific immunity, a secondary
analysis was performed and described a much higher efficacy
(64.3%) against malaria caused by parasites with the pfama-1
gene, corresponding to the 3D7 strain. This result led to the con-
clusion that vaccination with FMP2.1/AS02A elicited a significant
strain-specific resistance against P. falciparum malaria (20).
Very recently (in 2013), the results of clinical trials were pub-
lished on genetic immunization with the pfcsp and pfama-1 genes
in a heterologous prime-boost vaccination regimen. This protocol
consisted of priming with recombinant plasmid DNA, followed
by a booster immunization with human type 5 replication-defi-
cient adenovirus (AdHu5), both expressing the pfcsp and pfama-1
genes from P. falciparum strain 3D7. The results showed that 27%
of the individuals were sterilely protected upon experimental
challenge by exposure to the bite of mosquitos infected with the
homologous parasite strain (22).
In previous studies, we have shown that recombinant proteins
based on P. vivax AMA-1 are immunogenic in natural infection
(23–26). Furthermore, a prime-boost strategy using recombinant
AMA-1 administered in Montanide ISA720, followed by booster
injection of AdHu5 expressing PvAMA-1, produced high titers of
long-lasting antibodies and specific memory T cells (27).
The disadvantage of prokaryotic systems for recombinant pro-
tein production is the fact that the protein based on PvAMA-1
representing the entire ectodomain was insoluble (26). In spite of
efforts toward the standardization of an efficient protocol for sol-
ubilization/refolding, the yield was low, and endotoxin contami-
nation was reported (23, 26). In addition, the recognition of con-
formational epitopes may be critical for protective antibodies.
Accordingly, the expression of recombinant proteins using eu-
karyotic systems may represent a long-term advantage in an effort
to solve these problems. Indeed, a previous study expressed the
PvAMA-1 ectodomain in Pichia pastoris, and this antigen was im-
munogenic in rhesus monkeys when administered with the SBSA2
adjuvant (10).
Based on the promising results of vaccination with PfAMA-1
described above, we expressed and characterized the immuno-
genic properties of recombinant PvAMA-1 expressed as a soluble
protein in the yeast P. pastoris, aiming at the development of a
vaccine against P. vivax malaria.
MATERIALS AND METHODS
Synthesis, cloning, and yeast expression. The synthetic gene encoding
amino acids 43 to 487 of the PvAMA-1 ectodomain was synthetized by
GenScript USA, Inc. (Piscataway, NJ) with codon optimization to im-
prove expression in P. pastoris. The amino acid sequence was based on
that of a Brazilian P. vivax ama-1 isolate (23). Three potential N-glycosy-
lation sites were altered to prevent unwanted glycosylation (178N¡S,
226N¡D, and 441N¡Q) by using substituent amino acids from other
available AMA-1 sequences of malaria parasites (10). The constructs were
designed with appropriate restriction sites and a carboxyl-terminal His6
tag to enable purification. The synthetic gene cloned in the pUC57 vector
was removed by digestion with an NotI enzyme mix (New England Bio-
Labs) and subcloned into the NotI site of the P. pastoris expression vector
pPIC9K (Invitrogen). This expression vector contains the nucleotide se-
quence encoding the -factor signal peptide of Saccharomyces cerevisiae
for protein secretion, the AOX1 promoter for the control of gene ex-
pression, and the HIS4 gene for selection of the recombinant yeast
clones. A clone was selected containing the pvama-1 gene in the correct
orientation. The plasmid pPIC9K-pvama-1 was linearized with SalI to
transform the P. pastoris GS115 strain (his4) by electroporation. Ap-
proximately 350 His clones transformed with the plasmid pPIC9K-
pvama-1 were screened for high-copy-number integration by G418 selec-
tion; of these clones, two were resistant to 2 mg/ml G418. Based on an
immunoblotting analysis with mouse polyclonal anti-Escherichia coli
PvAMA-1, a clone secreting high levels of PvAMA-1 and possessing a
Mut phenotype was selected.
The expression and purification of the recombinant protein
PvAMA-1 were performed as previously described, with some modi-
fications (28). A Mut transformant was initially grown overnight in
200 ml BMGY medium (1% [wt/vol] yeast extract, 2% [wt/vol] pep-
tone, 1.34% [wt/vol] yeast nitrogen base without amino acids, 4 
105% [wt/vol] biotin, 1% [wt/vol] glycerol, 0.1 M potassium phos-
phate [pH 6.0]) at 28 to 30°C with vigorous shaking. The cells were
harvested, resuspended in 2 liters BMMY (BMGY with glycerol re-
placed by 0.5% [vol/vol] methanol), and incubated again for 72 h.
Methanol was added at a final concentration of 1% (vol/vol) every 24
h. After induction for 72 h, the cells were removed by centrifugation,
and the culture supernatant was concentrated by ultrafiltration with an
Amicon Ultracel 30,000-molecular-weight-cutoff (MWCO) membrane
(Millipore) and extensively dialyzed at 4°C against 20 mM sodium phos-
phate buffer (pH 8.0)– 0.2 M NaCl. The supernatant was applied to a
column with Ni2-nitrilotriacetic acid (NTA) agarose resin (Qiagen),
which was previously equilibrated (20 mM sodium phosphate buffer [pH
8.0], 0.5 M NaCl). The bound proteins were eluted with a 15 to 400 mM
imidazole (Sigma) gradient in wash buffer (20 mM sodium phosphate
buffer [pH 8.0], 0.5 M NaCl, 1 mM phenylmethylsulfonyl fluoride
[PMSF], 10% glycerol). Fractions containing the protein were pooled and
used in a second-step purification of anionic exchange chromatography
using Q FF resin (GE Healthcare) coupled to ÄKTA Prime Plus (GE
Healthcare). The protein was eluted using a 0 to 1 M NaCl linear gradient.
The peak corresponding to PvAMA1 with a high degree of purity was
collected and dialyzed against phosphate-buffered saline (PBS). The pro-
tein concentration was determined by the Bradford method (Bio-Rad)
using bovine serum albumin (BSA) (Sigma) as the standard.
Purified PvAMA-1 was analyzed by reverse-phase high-performance
liquid chromatography (RP-HPLC) using a Vydac C4 column (4.6 mm by
250 mm; 300-m particle size) and a Shimadzu LC solution HPLC system
(Shimadzu Corp., Kyoto, Japan). The HPLC procedure was performed
using an acetonitrile gradient from 0 to 100% in 0.1% trifluoroacetic acid
(TFA)–90% acetonitrile at room temperature (24°C) at 1 ml/min for 40
min. The elution was monitored with a UV-visible absorbance detector
(Shimadzu SPD M20A) at 214 nm.
The protocol for PvAMA-1 described above was validated in accor-
dance with the requirements of “conditions of good laboratory practice”
(cGLP) under contract with the Company Farmacore Biotecnologia, Ltd.
(Ribeirão Preto, São Paulo, Brazil). In this system, the final product is
subjected to analytical tests, SDS-PAGE and isoelectric focusing (IEF),
Western blotting, bicinchoninic acid (BCA) quantification, endotoxin de-
termination, and sterility. Vials containing the purified recombinant pro-
tein were stored at80°C.
Expression and purification of the PvAMA-1 ectodomain in E. coli
have been described elsewhere (23). The recombinant proteins were pu-
rified by Ni-affinity following published protocols.
CD spectroscopy. Circular dichroism (CD) spectroscopy was per-
formed using a JASCO-J720 spectropolarimeter. Recombinant PvAMA-1
diluted to 9.96M in PBS was loaded into a 5-mm quartz cuvette. Far-UV
measurements (8 scans) were performed over wavelengths of 260 to 200
nm with a 1-nm bandwidth, 1-s response time, and 20-nm/min scan
speed. The spectra were corrected by subtraction of the buffer signal. The
mean residue molar ellipticity, represented as []MRW, was calculated
(29), and the secondary structure was estimated by computer analysis
using CDNN software (Applied Photophysics, Ltd.).
Recombinant plasmid used for immunizations. The gene encoding
amino acids 43 to 487 of the PvAMA-1 ectodomain was obtained by PCR
Plasmodium vivax AMA-1 Vaccine Candidate
March 2014 Volume 82 Number 3 iai.asm.org 1297
using the plasmid pMOS-ama-1 as the target DNA (23). The two synthetic
oligonucleotide primers were 5=-GGAGGTACCCCTACCGTTGAGAGA
AGC-3= (forward) and 5=-AGTGGATCCTAGTAGCATCTGCTTGTTC
GA-3= (reverse) (Invitrogen). The oligonucleotide primers were synthe-
sized with a KpnI (forward) or BamHI (reverse) restriction site
(underlined). The resulting PCR amplification products were cloned
into pGEM-T Easy (Promega), and positive clones were selected by
DNA restriction endonuclease analysis and further confirmed by nu-
cleotide sequence analysis. The pvama-1 gene was removed from the
pGEM-T Easy vector by digestion with KpnI and BamHI and cloned
into the vector pIgSP (30) digested with the same enzymes. A colony
was selected with a plasmid containing the insert in the correct orien-
tation. This plasmid contains the sequence encoding the signal peptide
of the mouse immunoglobulin kappa chain in the commercial vector
pcDNA3 (Invitrogen). The plasmids were grown in E. coli DH5 and
purified using the Qiagen Plasmid Giga kit. The DNA concentration was
estimated at 260 nm.
Mice and immunization protocol. Female BALB/c (H-2d) mice at 6
to 8 weeks old were used in all the experiments; the animals were
purchased from the University of São Paulo, São Paulo, SP, Brazil.
Study protocol no. 112 was approved by the Ethics Committee of the
Faculty of Pharmaceutical Sciences of the University of São Paulo. The
immunogenicity of the recombinant PvAMA-1 protein was evaluated
in mice using homologous prime-boost protocols (DNA prime-DNA
boost and protein prime-protein boost) and heterologous prime-
boost strategies (DNA prime-protein boost or protein prime-DNA
boost). For the DNA immunizations, the pIgSP empty (Dctrl) or
pIgSP-ama-1 (D) plasmid was injected as previously described (30,
31). Briefly, both tibialis anterioris muscles were injected with 7 g
cardiotoxin (Sigma, St. Louis, MO); 5 days later, 100 g plasmid DNA
was injected intramuscularly at the same sites as the previous cardio-
toxin injections (D*). The effect of DNA administration in the absence
of cardiotoxin also was evaluated (D). Each mouse received four in-
tramuscular doses of plasmid DNA injected at 0, 3, 6, and 9 weeks
(D/D); in parallel, other groups of mice received the DNA prime-
protein boost (D/P) or the protein prime-DNA boost (P/D). The im-
munizations with the recombinant protein (P) were performed by a
subcutaneous (s.c.) route with 10 g of the protein in the absence of
any adjuvant or in the presence of incomplete Freund’s adjuvant (IFA)
(Sigma). A volume of 50 l was injected into each footpad. For com-
parison, one group was immunized with the protein emulsified in
complete Freund’s adjuvant (CFA) (Sigma), and the animals received
a booster injection of 10 g of the same protein emulsified in IFA,
injected s.c. at the base of the tail (P/P) after 3, 6, and 9 weeks. The
controls received only PBS emulsified in adjuvant. Twenty days after
each immunization, blood was collected from the tail, and the sera
were analyzed for the presence of antibodies against PvAMA-1 recom-
binant protein.
Subsequently, the immunizations were performed with the recombi-
nant PvAMA-1 protein formulated in different adjuvants, including 100
g Alhydrogel (Superfos Biosector, Denmark), 10 g Bordetella pertussis
monophosphoryl lipid A (MPLA), 5 g flagellin FliC from Salmonella
enterica serovar Typhimurium, 25 g saponin Quil A (Superfos Biosec-
tor, Denmark), and incomplete Freund’s adjuvant (IFA). MPLA was pro-
duced using lipopolysaccharide (LPS) from previously detoxified whole-
cell pertussis vaccine, as previously described (32). The PvAMA-1 protein
was also coadministered in aluminum salts (Alum) plus FliC or Alum plus
MPLA. These adjuvants were administered at the same doses used for the
immunizations with single adjuvants. The controls received only PBS
emulsified in adjuvant. The immunization schedule was the same as that
used in the heterologous prime-boost protocol, except that the interval
between the doses was 2 weeks for all of the different adjuvant formula-
tions. In summary, groups of BALB/c mice were immunized with one of
the following regimens: (i) 4 doses of plasmid DNA (pIgSP-pvama-1)
without (D/D) and with cardiotoxin (D*/D); (ii) 4 doses of PvAMA-1
protein in the absence or presence of CFA/IFA (P/P); (iii) one dose of
PvAMA-1 protein in the absence or presence of IFA, followed by 3 doses of
pIgSP-pvama-1 (P/D); (iv) one dose of pIgSP-pvama-1 immunization,
followed by 3 doses of PvAMA-1 protein in the presence of IFA (D*/P); or
(v) one dose of plasmid pIgSP followed by 3 doses of PvAMA-1 protein
emulsified in IFA (Dctrl*/P).
Immunological assays. (i) Immunoblotting analysis. Protein frac-
tions were fractionated by 12% SDS-PAGE under reducing or nonreduc-
ing conditions and transferred from the gel to nitrocellulose membranes
(Hybond N; GE Healthcare) with the aid of a Mini Trans-Blot apparatus
(Bio-Rad). The membranes were saturated for 2 h at room temperature in
PBS-milk-BSA (5% [wt/vol] nonfat milk and 2.5% [wt/vol] bovine serum
albumin). The membranes were then incubated with a mouse monoclo-
nal anti-histidine (anti-His) tag (GE Healthcare) at a final dilution of
1:1,000 or with monoclonal antibodies (MAbs) against PvAMA-1 domain
II (33). After 1 h at room temperature, the membranes were washed three
times with PBS– 0.05% (vol/vol) Tween 20 (PBS-Tween), and goat anti-
mouse IgG coupled to peroxidase was added to the membranes at a final
dilution of 1:2,000 (KPL, Gaithersburg, MD). After 1 h of incubation at
room temperature, the reaction was developed using the ECL enhanced
chemiluminescence detection assay (GE Healthcare).
(ii) Detection of human anti-PvAMA-1 antibodies by ELISA. Serum
samples were previously collected from 208 individuals with patent P.
vivax malaria living in regions of endemicity in the state of Pará (northern
Brazil). Clinical and laboratory data have been reported elsewhere for all
individuals (34). The study protocol was approved by the Ethics Commit-
tee of the Faculty of Pharmaceutical Sciences of the University of São
Paulo (CEP no. 354/2006). The detection of human IgG antibodies spe-
cific for the recombinant proteins was performed by enzyme-linked im-
munosorbent assay (ELISA), as described previously (26). The ELISA
plates were coated with 100 ng/well of PvAMA-1; for comparison, a bac-
terial recombinant protein previously produced (23, 26) was also tested
against the same sera. A 50-l aliquot of each solution was added to each
well of Costar high-binding 96-well plates. After an overnight incubation
at room temperature, the plates were washed with PBS-Tween and
blocked with 5% nonfat milk in PBS (PBS-milk) for 2 h at 37°C. Serum
samples were added to each well in duplicate at a final dilution of 1:100.
After incubation for 2 h at room temperature and washes with PBS–
0.05% Tween 20, we added 50 l of a solution containing peroxidase-
conjugated goat anti-human IgG (Fc specific; Sigma) at a final dilution of
1:5,000 to each well. The enzymatic reaction was developed with o-phe-
nylenediamine (1 mg/ml) (Sigma) diluted in phosphate-citrate buffer
(pH 5.0) containing hydrogen peroxide (0.03% [vol/vol]). The enzymatic
reaction was stopped by the addition of 50l of a solution containing 4 N
H2SO4. The optical density at 492 nm (OD492) was measured using an
ELISA reader (Awareness Technology, model Stat Fax 3200, EUA). The
cutoff points were set at 3 standard deviations (SD) above the mean OD492
value of the sera from 25 healthy individuals from the city of São Paulo
who had never been exposed to malaria (34).
(iii) Determination ofmouse antibody titers against PvAMA-1. An-
tibodies against PvAMA-1 in mouse sera were detected by ELISA, essen-
tially as described previously (26, 33). The recombinant PvAMA-1 pro-
teins were employed as solid-phase-bound antigen (100 ng/well), and a
volume of 50 l of each solution was added to each well of 96-well plates.
After overnight incubation at room temperature, the plates were washed
with PBS-Tween and blocked with PBS-milk–2.5% BSA for 2 h at 37°C.
The polyclonal sera of the mice were tested at serial dilutions in a final
volume of 50 l of sample added to each well in duplicate, followed by
incubation for 1 h at room temperature. After washes with PBS-Tween, 50
l of a solution containing the secondary antibody conjugated to perox-
idase (goat anti-mouse IgG; KPL) diluted 1:3,000 was added to each well.
The enzymatic reaction was developed as described above. The anti-
PvAMA-1 titers were determined as the highest dilution yielding an
OD492 higher than 0.1. The results are expressed as means of IgG titers
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(log10)	 standard errors of the mean (SEM) detected at 2 weeks after each
immunizing dose.
(iv) Indirect immunofluorescence assay. Immunofluorescence as-
says were performed as described previously (27). Merozoite preparations
were made from ex vivo matured and concentrated schizonts as described
in the section v below. The thin-smear preparations of free merozoites and
mature schizont-infected erythrocytes were fixed with cold acetone for 15
min and blocked with 3% BSA in PBS for 30 min at 37.5°C in a humidified
FIG 1 The recombinant protein was expressed in P. pastoris with a hexahistidine tag and purified from the supernatant by affinity chromatography, followed by
anion-exchange chromatography, as described in Materials and Methods. (A) SDS-PAGE analysis of purified recombinant PvAMA-1 stained with Coomassie
blue (1 g of protein per lane). (B) Immunoblotting analysis of purified recombinant PvAMA-1 using an anti-histidine tag antibody. (C) RP-HPLC profile of
purified recombinant PvAMA-1. Purified PvAMA-1 produced under cGLP was analyzed by RP-HPLC using a C4 column, as described in Materials and Methods.
(D) Circular dichroism spectrum of recombinant PvAMA-1. The spectrum was recorded from 200 to 260 nm using a JASCO-J720 spectropolarimeter. The plot
represents the mean residue ellipticity of the recombinant protein.
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incubator. Sera from animals immunized with AMA-1 plus Quil A or
AMA-1 plus MPLA (dilution, 1:100) were applied to the slides and incu-
bated for 1 h. The slides were then washed 3 times with PBS before the
addition of anti-mouse IgG conjugated to Alexa Fluor 568 (Molecular
Probes) diluted 1:500 with 3% BSA in PBS or DAPI (4=,6-diamidino-2-
phenylindole) (Invitrogen). Binding was visualized using a Nikon TS 100
epifluorescence microscope.
(v) Inhibition invasion assay. Four clinical isolates from P. vivax-
infected blood from malaria patients attending the clinics of the Shoklo
Malaria Research Unit (SMRU), Mae Sot region northwest of Thailand,
were collected after written informed consent (OXTREC 027-025; Uni-
versity of Oxford, Centre for Clinical Vaccinology and Tropical Medicine,
Oxford, United Kingdom). These blood samples were collected by veni-
puncture in 5-ml-volume lithium heparinized tubes, which were trans-
ported to the laboratory at SMRU within 5 h of collection. White blood
cells and platelets were removed using a CF11 column (35). The P. vivax-
infected erythrocytes were cultured to the late schizont stage in 2% he-
matocrit (Hct) McCoy’s 5A medium supplemented with 2.4 g/liter D-glu-
cose, 40 mg/ml gentamicin sulfate, and 20% heat-inactivated human AB
serum, in an atmosphere of 5% O2 at 37.5°C for 
44 h. The mature
schizonts were concentrated on a cushion of 45% Percoll (isotonic) cen-
trifuged for 15 min at 1,600 g (36). After being washed twice in McCoy’s
5A medium, thin-smear preparations of the schizont concentrate were
split into two portions (
5 l each). The first portion was smeared onto
glass slides, air dried, and fixed with cold acetone for 15 min and stored at
20°C until needed (These were used in the “Indirect fluorescence assay”
section above). The remainder of the schizont concentrate was then uti-
lized in a P. vivax invasion assay that utilized reticulocytes enriched from
one isolate of human cord blood (37). In addition to the treatment
(AMA-1 plus Quil A [1:100]) and untreated control, it is vital to use the
positive control (25 g/ml of antibody 2C3, a monoclonal antibody
against the Duffy antigen receptor [DARC]), which almost always blocks
P. vivax invasion in this isolate (a kind gift from Yves Colin and Olivier
Bertrand, INSERM UMR-S665 and Institut National de la Transfusion
Sanguine, Paris, France). To provide for an objective and quantitative
measure of P. vivax invasion in the treatments and controls after 24 h of
incubation, we used the tricolor flow cytometry method using a field-
deployable flow cytometer (BD Accuri C6 flow cytometer) (38). In addi-
tion, the flow cytometry data were cross-checked with Giemsa-stained
smears using microscopy.
FIG 2 Immunoblotting analysis of recombinant PvAMA-1 using monoclonal antibodies and a comparative evaluation of PvAMA-1 expressed in E. coli or P.
pastoris for recognition by human sera. (A) Recombinant PvAMA-1 was subjected to 12% SDS-PAGE performed under reducing (R) and nonreducing (NR)
conditions. Immunoblotting was performed using the indicated monoclonal antibodies. (B) Sera from 208 individuals with patent P. vivax malaria from areas
of endemicity in Brazil were tested against recombinant PvAMA-1 produced in E. coli or P. pastoris. The values are the OD492 measurements of each protein. The
tendency line and the value of the Spearman correlation coefficient (r) are represented.
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Statistical analysis. Correlations were determined by the nonpara-
metric Spearman correlation coefficient. A one-way analysis of variance
(ANOVA) was used to compare possible differences in the mean values,
with the level of significance set at P 0.05.
Nucleotide sequence accession number. The sequence for yPvAMA-1
was deposited into GenBank under accession number KJ010958.
RESULTS
Expression, purification, and biochemical characterization of
recombinant PvAMA-1. To improve protein expression, we used
a codon-optimized gene for secreted expression in the methyl-
otrophic yeast P. pastoris based on the previously described
pvama-1 sequence (23). Only the ectodomain of PvAMA-1 was
synthesized, representing amino acids 43 to 487. This amino acid
sequence has three putative N-linked glycosylation sites, and
we performed conservative mutations to remove these sites
(178N¡S, 226N¡D, and 441N¡Q) using substituent amino ac-
ids from available AMA-1 sequences of other malaria parasites
(10). The final construct also encodes six amino acids that include
the N-terminal hexahistidine tag for Ni2-chelating chromatog-
raphy. The synthetic pvama-1 gene was subcloned into the com-
mercial expression vector pPIC9K in frame with the nucleotides
encoding the yeast -factor secretion signal peptide.
The protein was expressed as a secreted, soluble protein, and
the yield (7 mg/liter) was superior to that obtained previously inE.
coli (23). The protein was purified as described in Materials and
Methods, and the final protein purity was 90% according to
SDS-PAGE and Coomassie blue staining, which revealed a pre-
dominant band that migrated at approximately 53 kDa under re-
ducing conditions (Fig. 1A). Using an immunoblotting analysis,
the protein was detected by an anti-His tag MAb, indicating that
the His6 tag had been preserved (Fig. 1B).
The homogeneity of the recombinant protein was confirmed
by reverse-phase chromatography on a C4 column, and a single
peak was observed, as shown in Fig. 1C. To investigate the folding
of recombinant PvAMA-1, we examined the protein by far-UV
CD spectroscopy (Fig. 1D). The CD data were deconvoluted using
the CDNN program (Applied Photophysics, Ltd.), and the per-
centages of -helix, anti-parallel -sheet, parallel -sheet, -turn,
and random coil were estimated. The PvAMA-1 CD spectrum is
consistent with a folded protein and predicts approximately
12.4% -helix, 20.7% anti-parallel -sheet, 19.6% parallel
-sheet, 22.5% -turn, and 54.2% random coil structures. These
data are consistent with the secondary structure of PvAMA-1
(strain SalI) crystallized by Pizarro et al. in 2005 (39).
Antigenic characterization. Immunoblotting probed with
two anti-PvAMA-1 domain II MAbs which recognize fixed para-
sites by IFA (33) showed that they reacted strongly with PvAMA-1
under reducing or nonreducing conditions (MAbs K239 and
K243), suggesting that these MAbs recognize nonconformational
epitopes associated with the entire PvAMA-1 antigen (Fig. 2A).
The same results were obtained with MAbs K214, K268, and K278
(data not shown).
Purified PvAMA-1 produced in E. coli and P. pastoris were
examined by ELISA with sera collected from 208 individuals dur-
ing patent P. vivax infection (25). The results showed that 72.7%
and 62.5% of the sera recognized E. coli PvAMA-1 and P. pastoris
PvAMA-1, respectively. A high Spearman correlation coefficient
(r) was obtained when we compared the reactivities of human
antibodies to both recombinant proteins (r  0.94), indicating
that the recombinant protein produced in yeast maintains its an-
tigenic properties (Fig. 2B).
Immunogenic properties. Mice were immunized using differ-
ent schedules to provide a direct comparison of the relative im-
munogenicities of homologous (D/D or P/P) versus heterologous
(D/P or P/D) prime-boost vaccinations. Groups of BALB/c mice
were immunized with the following: (i) plasmid DNA (pIgSP-
pvama-1) without (D/D) and with cardiotoxin (D*/D), (ii)
PvAMA-1 protein in the absence or presence of CFA/IFA (P/P);
(iii) PvAMA-1 protein in the absence or presence of IFA followed
by pIgSP-pvama-1 (P/D), (iv) pIgSP-pvama-1 immunization, fol-
lowed by PvAMA-1 protein in the presence of IFA (D*/P), and (v)
plasmid pIgSP followed by PvAMA-1 protein emulsified in IFA
(Dctrl*/P).
The first two schedules are homologous prime boosting using
the same type of vaccine. The third and fourth schedules are het-
erologous prime boosting with DNA or recombinant protein ad-
ministered for priming, followed by three heterologous booster
immunizations. Two additional immunization schedules were in-
cluded as controls. The mice received only plasmid DNA vector
(pIgSP) immunizations (Dctrl*/Dctrl), and another control group
received only PBS in CFA/IFA.
The comparative immunogenicity in each animal group was
determined by the mean of the serum IgG antibody titers of each
individual mouse against the PvAMA-1 antigen estimated by
ELISA. After 4 immunizing doses with the different immunization
protocols, we observed that the D*/P (IFA) and P/P (CFA/IFA)
protocols induced significantly higher serum IgG antibody titers
than the D*/D, P/D, and P/P (without adjuvant) regimens (Fig. 3).
These results showed that the efficiency of the PvAMA-1 immu-
nization is highly dependent on a formulation containing the re-
FIG 3 Serum IgG titers of mice immunized with recombinant PvAMA-1
and/or plasmid DNA containing the pvama-1 gene. Mice were immunized 4
times with 100 g of DNA (D) i.m. or 10 g of recombinant protein (P) s.c.
with a 20-day interval. The protein was administered without adjuvant or
emulsified in CFA/IFA. Five days prior to immunization with DNA, some
groups received cardiotoxin (D*). The animals from control groups were im-
munized with empty DNA vector (Dctrl) or CFA/IFA diluted in PBS. The
results are expressed as the mean log10 titers	 SEM. n.s., nonsignificant (P
0.05). ***, P 0.001.
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combinant protein in adjuvant. In spite of the observation that the
mice receiving the DNA prime immunization followed by booster
immunization with PvAMA-1 protein in IFA (D*/P) presented
slightly higher antibody responses than those of the control group
(Dctrl*/P), the endpoint serum dilution titers among these groups
were not statistically different after the second dose. Thus, we
concluded that priming with plasmid DNA did not improve vac-
cination (Fig. 3). The animals that received immunizations with
only the empty DNA vaccine vector (Dctrl*/Dctrl) or pIgSP-
pvama-1 without cardiotoxin (D/D) did not present specific anti-
bodies against PvAMA-1. Additionally, the recombinant protein
alone showed negligible immunogenicity in the absence of adju-
vant, highlighting the extreme importance of the choice of adju-
vant in the formulation of malaria vaccines used in preclinical
immunization against P. vivax.
The identification of potent adjuvants capable of inducing an-
tibody responses as high as Freund’s adjuvant is considered a great
challenge in the development of subunit vaccines for malaria.
Thus, we evaluated the immunogenicity of PvAMA-1 in mice in
the presence of other adjuvants, including aluminum salts
(Alum), Bordetella pertussis MPLA, flagellin FliC from Salmonella
Typhimurium, saponin Quil A, and IFA, for comparison. BALB/c
mice were immunized subcutaneously with each formulation, and
the IgG antibodies titers against PvAMA-1 were detected by ELISA
15 days after each dose. At the end of the immunization schedule,
we observed that the formulation containing Quil A or IFA dis-
played higher serum IgG antibody titers (5.21	 0.06 and 5.41	
0.06, respectively) (Fig. 4A). No statistically significant differences
in the mean antibody titers were detected among the mice im-
munized with formulations containing PvAMA-1 and Quil A
or IFA (P 0.05, one-way ANOVA). Lower but still significant
antibody titers were obtained using Alum, MPLA, Alum plus
MPLA, or Alum plus FliC (4.36 	 0.05, 4.78 	 0.07, 4.66 	
0.05, or 4.51 	 0.06, respectively). The lowest antibody titers
were obtained using the protein coadministered in FliC
(3.05 	 0.07). The comparison of the mean values of the anti-
body titers of the mice immunized with PvAMA-1 in the pres-
ence of MPLA or MPLA plus Alum did not reveal a statisti-
cally significant difference among them (P  0.05, one-way
ANOVA). Moreover, the use of MPLA alone, instead of in com-
bination with Alum, reduced the IgG1/IgG2a ratios from 794 to
125 (Fig. 4B). As expected, IgG1 isotypes predominated in the
sera of the animals immunized with the formulation contain-
ing PvAMA-1 and Alum (Alum alone, Alum plus MPLA, or
Alum plus FliC). In contrast, more balanced IgG isotype re-
sponses were induced with the formulations containing Quil A
or IFA, characterizing a mixed Th1-Th2 response (Fig. 4B).
To confirm that our recombinant protein could be further
used for vaccine development, PvAMA-1 was produced under
“conditions of good laboratory practice” (cGLP) by the company
Farmacore Biotecnologia, Ltd. Following our protocol, a batch of
protein with a good yield, low endotoxin levels, and high purity
was obtained (Table 1). The results of experimental immuniza-
tions using this antigen in the presence of selected adjuvants
(MPLA, Quil A, and IFA) confirmed the high immunogenicity of
PvAMA-1 (Fig. 4C).
In addition, the sera from mice immunized with PvAMA-1 in
formulations containing MPLA or Quil A (Fig. 5) and Alum or
Alum plus MPLA (see Fig. S1 in the supplemental material) were
able to recognize the native protein exposed on the surface of P.
vivax merozoites isolated from infected donors from Thailand. To
evaluate the ability of the antibodies raised against PvAMA1 to
inhibit the reinvasion of new erythrocytes, we used four different
isolates from infected donors from Thailand and tested a pool of
sera from mice immunized with PvAMA-1 (cGLP) in a formula-
tion containing Quil A. The results showed successful inhibition,
ranging from 10.79% to 43.38% compared to the prebleed serum
negative control (Fig. 6).
DISCUSSION
In previous studies, we showed that recombinant proteins ex-
pressed in E. coli based on the P. vivax AMA-1 sequence were
recognized by IgG antibodies of a large fraction of malaria-in-
fected individuals (23–26). We also described that these recombi-
nant proteins can induce high antibody titers in mice following a
homologous (protein-protein) or heterologous (protein-adeno-
virus) regimen of vaccination (27). Unfortunately, when pro-
duced in E. coli, the ectodomain of PvAMA-1 is insoluble and
requires denaturation and refolding for purification (23, 26).
Thus, to attempt to solve this problem, the present study was
designed to express a soluble form of the ectodomain of PvAMA-1
as a secreted polypeptide in the yeast P. pastoris.
Using this system, we successfully generated a soluble antigenic
protein under cGLP that exhibited a high degree of purity and low
endotoxin and microbial contents. The yeast-derived PvAMA-1
protein retained its antigenicity, as it was recognized by the IgG
FIG 4 Serum IgG titers of mice immunized with recombinant PvAMA-1 using formulations containing different adjuvants. (A) Groups of BALB/c mice were
immunized s.c. with 10 g of the PvAMA-1 protein in the presence of different adjuvants, as described in Materials and Methods. These adjuvants were tested
alone or in combination (AlumMPLA and Alum FliC). The results are expressed as the mean log10 titers	 SEM. n.s., nonsignificant (P 0.05). ***, P
0.001. (B) Comparative serum IgG subclass profile after mouse immunization with PvAMA-1 using different adjuvants. The results are expressed as the
IgG1/IgG2a ratio of titer	 SEM. (C) Immunogenicity of the PvAMA-1 protein produced under “conditions of good laboratory practice” (cGLP). The results are
expressed as mean log10 antibody titers	 SEM. n.s., nonsignificant (P 0.05); *, P 0.05; ***, P 0.001.
TABLE 1 Characteristics of the final product of the PvAMA-1 vaccine
obtained under cGLP
Characteristic Result Method
Concn 1.69 mg/ml Micro-BCA
protein assay
kit
Purity by SDS-PAGE 85% Phast System (GE
Healthcare)
Molecular size Single 52-kDa band SDS-PAGE
Binding to monoclonal
anti-His
Positive Western blot
Endotoxin content 7.21 EUa/mg Kinetic-QCL kit
Sterility Sterile Bioburden test
Product potency Induction of high IgG antibody
titers (log10,5) in mice
following s.c. immunization
ELISA
a EU, endotoxin units.
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antibodies from 62.5% of individuals infected with P. vivax. The
recognition was comparable to the E. coli-derived PvAMA-1 re-
combinant protein (r 0.94), indicating the presence of epitopes
in both proteins shared with native PvAMA-1.
The evaluation of immunogenicity in mice showed that IFA
and Quil A induced higher IgG titers and a more balanced Th1/
Th2 response. Relevant for vaccine development was the observa-
tion that lower but also significant titers were obtained in the
presence of the adjuvants licensed for human use: Alum, MPLA,
or the combination of Alum plus MPLA. Formulations with the
adjuvants Alum or Alum plus MPLA predominantly induced a
Th2 response, and the use of MPLA alone balanced this response.
Formulations containing MPLA can be used for human vaccina-
tion trials, and the MPLA we used was recently developed and
investigated in human trials as an adjuvant for an influenza vac-
cine (40). Formulations containing either MPLA, Alum, and
squalene or MPLA plus Alum have been proven to be safe and
immunogenic for humans (40).
Although high antibody titers are important, protective immu-
nity against infection will only be achieved if these antibodies recog-
nize the native protein and inhibit parasite invasion of reticulocytes.
The immunofluorescence results confirmed the recognition of native
protein from P. vivax isolates from Thailand by the sera of immu-
nized mice. Because our protein was based on an Amazonian iso-
late of P. vivax, these results reflect the presence of cross-reactive
epitopes.
It has long been known that antibodies against Plasmodium
AMA-1 have a strong invasion-inhibitory activity (3). However,
one of the greatest limitations for P. vivax vaccine development
has been the lack of a functional in vitro assay to routinely assess
the invasion-inhibitory activity of the antibodies. To overcome
this limitation, we took advantage of a recently described ex vivo
reinvasion assay (37) to test whether the sera of mice immunized
with PvAMA-1 presented invasion-inhibitory activity. We found
that the antibodies obtained from mice immunized with
PvAMA-1 in the presence of Quil A inhibited the reticulocyte
invasion of four different isolates from Thailand, results that were
for the first time obtained with P. vivax. Our results of parasite
inhibition are compatible with our own previous studies using
immune IgG against region II of the Duffy binding protein (37).
Essentially, these findings confirm and extend the previous studies
of other species of Plasmodium, providing further support for the
implementation of PvAMA-1 as a vaccine candidate against P.
vivax malaria.
However, the main problem with using AMA-1 as a malaria
vaccine component is the known allelic polymorphism, which
may generate allele-specific invasion-inhibitory antibodies. In
fact, as mentioned in the introduction, the results obtained in a
phase II trial using the vaccine FMP2.1/AS02A, a recombinant
protein of PfAMA-1 based on the 3D7 allele, strongly argue in
favor of the interpretation of strain-specific resistance against ma-
laria infection (20).
Obviously, because P. vivax research has been highly ne-
glected, to our knowledge, nothing is known regarding the immu-
nological impact of the allelic differences of PvAMA-1. Indeed, it
is unknown whether a similar strain-specific immunity will be
induced by vaccination with the recombinant protein we de-
scribed herein. Therefore, it would not be proper to speculate at
this time.
In spite of the problems faced by allelic polymorphisms, the
potential of AMA-1 as a vaccine component against P. falciparum
malaria continues to attract a number of important research
groups in this field. These laboratories are investing different ap-
proaches to overcome the problem imposed by the allelic poly-
morphism of PfAMA-1 (41–43). In addition, recent studies using
parasites isolated from individuals vaccinated with FMP2.1/
AS02A mapped few amino acid variations as the cause of strain-
specific resistance (44). Such limited polymorphism raises the
FIG 5 Indirect immunofluorescence analysis using sera from BALB/c mice immunized with the cGLP PvAMA-1 protein in formulations containing different
adjuvants. The second row of panels shows a magnified region of the corresponding panels above. These magnified images highlight the apical staining pattern
of anti-PvAMA-1 plus MPLA. Microscope slides containing fixed P. vivax cells obtained from patients from Thailand were incubated with sera from mice
immunized with PvAMA-1 in the presence of MPLA or Quil A (diluted 1:100). BF, bright field.
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possibility that a few recombinant proteins representing key al-
leles would cover the entire population of P. falciparum. In the
worst-case scenario, if similar problems of strain-specific immu-
nity arise due to allelic polymorphism of the PvAMA-1 protein,
perhaps solutions similar to those developed for P. falciparum
AMA-1 can be adopted for P. vivax.
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